Cargando…

Ferroptosis and tumor immunotherapy: A promising combination therapy for tumors

Low response rate and treatment resistance are frequent problems in the immunotherapy of tumors, resulting in the unsatisfactory therapeutic effects. Ferroptosis is a form of cell death characterized by the accumulation of lipid peroxides. In recent years, it has been found that ferroptosis may be r...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Huazhong, Ren, Yongfei, Chen, Shuangwei, Wang, Yue, Chu, Liangmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945274/
https://www.ncbi.nlm.nih.gov/pubmed/36845720
http://dx.doi.org/10.3389/fonc.2023.1119369
_version_ 1784892105185820672
author Cai, Huazhong
Ren, Yongfei
Chen, Shuangwei
Wang, Yue
Chu, Liangmei
author_facet Cai, Huazhong
Ren, Yongfei
Chen, Shuangwei
Wang, Yue
Chu, Liangmei
author_sort Cai, Huazhong
collection PubMed
description Low response rate and treatment resistance are frequent problems in the immunotherapy of tumors, resulting in the unsatisfactory therapeutic effects. Ferroptosis is a form of cell death characterized by the accumulation of lipid peroxides. In recent years, it has been found that ferroptosis may be related to the treatment of cancer. Various immune cells (including macrophages and CD8(+) T cells) can induce ferroptosis of tumor cells, and synergistically enhance the anti-tumor immune effects. However, the mechanisms are different for each cell types. DAMP released in vitro by cancer cells undergoing ferroptosis lead to the maturation of dendritic cells, cross-induction of CD8(+) T cells, IFN-γ production and M1 macrophage production. Thus, it activates the adaptability of the tumor microenvironment and forms positive feedback of the immune response. It suggests that induction of ferroptosis may contribute to reducing resistance of cancer immunotherapy and has great potential in cancer therapy. Further research into the link between ferroptosis and tumor immunotherapy may offer hope for those cancers that are difficult to treat. In this review, we focus on the role of ferroptosis in tumor immunotherapy, explore the role of ferroptosis in various immune cells, and discuss potential applications of ferroptosis in tumor immunotherapy.
format Online
Article
Text
id pubmed-9945274
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99452742023-02-23 Ferroptosis and tumor immunotherapy: A promising combination therapy for tumors Cai, Huazhong Ren, Yongfei Chen, Shuangwei Wang, Yue Chu, Liangmei Front Oncol Oncology Low response rate and treatment resistance are frequent problems in the immunotherapy of tumors, resulting in the unsatisfactory therapeutic effects. Ferroptosis is a form of cell death characterized by the accumulation of lipid peroxides. In recent years, it has been found that ferroptosis may be related to the treatment of cancer. Various immune cells (including macrophages and CD8(+) T cells) can induce ferroptosis of tumor cells, and synergistically enhance the anti-tumor immune effects. However, the mechanisms are different for each cell types. DAMP released in vitro by cancer cells undergoing ferroptosis lead to the maturation of dendritic cells, cross-induction of CD8(+) T cells, IFN-γ production and M1 macrophage production. Thus, it activates the adaptability of the tumor microenvironment and forms positive feedback of the immune response. It suggests that induction of ferroptosis may contribute to reducing resistance of cancer immunotherapy and has great potential in cancer therapy. Further research into the link between ferroptosis and tumor immunotherapy may offer hope for those cancers that are difficult to treat. In this review, we focus on the role of ferroptosis in tumor immunotherapy, explore the role of ferroptosis in various immune cells, and discuss potential applications of ferroptosis in tumor immunotherapy. Frontiers Media S.A. 2023-02-08 /pmc/articles/PMC9945274/ /pubmed/36845720 http://dx.doi.org/10.3389/fonc.2023.1119369 Text en Copyright © 2023 Cai, Ren, Chen, Wang and Chu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Cai, Huazhong
Ren, Yongfei
Chen, Shuangwei
Wang, Yue
Chu, Liangmei
Ferroptosis and tumor immunotherapy: A promising combination therapy for tumors
title Ferroptosis and tumor immunotherapy: A promising combination therapy for tumors
title_full Ferroptosis and tumor immunotherapy: A promising combination therapy for tumors
title_fullStr Ferroptosis and tumor immunotherapy: A promising combination therapy for tumors
title_full_unstemmed Ferroptosis and tumor immunotherapy: A promising combination therapy for tumors
title_short Ferroptosis and tumor immunotherapy: A promising combination therapy for tumors
title_sort ferroptosis and tumor immunotherapy: a promising combination therapy for tumors
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945274/
https://www.ncbi.nlm.nih.gov/pubmed/36845720
http://dx.doi.org/10.3389/fonc.2023.1119369
work_keys_str_mv AT caihuazhong ferroptosisandtumorimmunotherapyapromisingcombinationtherapyfortumors
AT renyongfei ferroptosisandtumorimmunotherapyapromisingcombinationtherapyfortumors
AT chenshuangwei ferroptosisandtumorimmunotherapyapromisingcombinationtherapyfortumors
AT wangyue ferroptosisandtumorimmunotherapyapromisingcombinationtherapyfortumors
AT chuliangmei ferroptosisandtumorimmunotherapyapromisingcombinationtherapyfortumors